Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) (2013)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1093/annonc/mdt182
- Subjects: NEOPLASIAS MAMÁRIAS (DIAGNÓSTICO;QUIMIOTERAPIA); ANTINEOPLÁSICOS (DIAGNÓSTICO)
- Language: Inglês
- Imprenta:
- Source:
- Título: Annals of Oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 24, n. 9, p. 2278-2284, 2013
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SCHNEEWEISS, A. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology, v. 24, n. 9, p. 2278-2284, 2013Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdt182. Acesso em: 11 fev. 2026. -
APA
Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., et al. (2013). Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology, 24( 9), 2278-2284. doi:10.1093/annonc/mdt182 -
NLM
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y-F, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) [Internet]. Annals of Oncology. 2013 ; 24( 9): 2278-2284.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1093/annonc/mdt182 -
Vancouver
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y-F, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) [Internet]. Annals of Oncology. 2013 ; 24( 9): 2278-2284.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1093/annonc/mdt182 - Eficacia, tolerabilidade e aceitabilidade do estradiol transdermico no tratamento dos sintomas da menopausa
- Sindrome do climaterio: conceito, importancia e epidemiologia
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
- Câncer da mama: quadro clínico, diagnóstico e estadiamento
- Mastite puerperal
- Galactorreia: sindrome hiperprolactinemica
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
Informações sobre o DOI: 10.1093/annonc/mdt182 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
